Lack of association of Ang-2 level during remission (and off prednisone) with time to flare of ANCA-associated vasculitis (AAV) in the RAVE trial.

*Variables were continuous for age and Ang-2, dichotomous for the others; RTX = rituximab (referent = cyclophosphamide/azathioprine); referent for PR3 ANCA is MPO ANCA; relapsing AAV refers to status at screening (referent = new diagnosis of AAV).
†HR = hazard ratio, CI = confidence interval, using Cox proportional hazards models; ND = not done because P value of covariate in univariable model was >0.2 (Ang-2 was included in all models).
‡Severe flare = BVAS/WG≥3.